“Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections
A Phase 2 Randomized Clinical Trial”
A small randomized clinical trial involving 450 participants compared use of azelastine nasal spray with placebo spray administered 3 times daily over 56 days. The development of confirmed infection with SARS-CoV-2 (COVID) was 67% lower in the azelastine treated group versus the placebo treated group. Secondarily there was noted to be a 71% reduction in confirmed rhinovirus infections in the azelastine treated group versus the placebo treated group.
Although findings remain to be replicated in a larger scale, multi-center study, these initial results are encouraging regarding a safe potentially effective means of preventing COVID 19 infections apart from vaccination. [JAMA Intern Med. 2025 Sep 2:e254283.]
WARNING: None of the information on this website should be construed as medical advice. Such advice is always individualized and should come directly from your own personal physician